Medicine and Dentistry
Pediatrics
100%
Neoplasm
94%
Ganglioglioma
60%
Medulloblastoma
58%
Radiation Therapy
46%
Oncology
43%
Oligoastrocytoma
39%
Pontine Glioma
32%
Glioblastoma
26%
Surgery
26%
Pediatrics Patient
22%
Malignant Neoplasm
21%
Temozolomide
19%
Brain Tumor
18%
Ependymoma
15%
Disease
15%
Overall Survival
15%
Magnetic Resonance Imaging
15%
Pilocytic Astrocytoma
14%
Event Free Survival
14%
Clinical Trial
13%
Central Nervous System Tumor
13%
Pediatric Brain Tumor
12%
Progression Free Survival
12%
Histopathology
11%
Pediatric Cancer
10%
Toddlers
10%
Anaplastic Carcinoma
9%
Biological Marker
9%
Atypical Teratoid Rhabdoid Tumor
9%
Brainstem Glioma
9%
Central Nervous System Cancer
9%
Chemoradiotherapy
8%
Biopsy
8%
Survival Rate
8%
Tumor Cell
8%
Phase II Trials
8%
Childhood Cancer
7%
Brainstem
7%
Emergency Medical Technician
7%
Adjuvant Therapy
7%
Pharmacokinetics
6%
Recurrent Disease
6%
Solid Malignant Neoplasm
6%
Chemotherapy Regimens
6%
Bevacizumab
6%
Cancer
6%
Adolescent
6%
Long Term Survival
6%
Central Nervous System
6%
Keyphrases
Medulloblastoma
55%
Tumor
49%
Pediatric
33%
Pediatric Patients
31%
Diffuse Intrinsic Pontine Glioma
28%
Children's Oncology Group
27%
Newly Diagnosed
21%
Phase II Study
21%
High-grade Glioma
19%
Pediatric Glioma
19%
Temozolomide
15%
Chemotherapy
14%
Pilocytic Astrocytoma
14%
Brain Tumor
14%
Gross Total Resection
14%
Malignant Glioma
14%
Group Studies
13%
Radiation Therapy
12%
Event-free Survival
11%
Progression-free Survival
10%
Pediatric Low-grade Glioma
10%
Pediatric Brain Tumor
10%
Pharmacokinetics
10%
High-grade Astrocytoma
9%
Pediatric Cancer
9%
Central Nervous System Tumors
9%
Atypical Teratoid Rhabdoid Tumor (AT/RT)
9%
Dabrafenib Plus Trametinib
9%
BRAFV600
9%
Comparative Genomic Hybridization
9%
Phase I Study
9%
Anaplasia
9%
Primitive Neuroectodermal Tumor
9%
Children with Cancer
8%
Phase II Trial
8%
C-Myc
7%
Myxopapillary Ependymoma
7%
Adjuvant Therapy
7%
Irradiation
7%
Overall Survival
6%
Dose Finding
6%
Objective Response Rate
6%
Molecular Characterization
6%
Working Diagnosis
6%
Bevacizumab
6%
Anaplastic
6%
Overexpression
6%
Chromosome Rearrangement
6%
Long-term Survival
6%
Oncology
6%